« Back to Medicines list

Coversyl Arginine 10mg orodispersible tablets

  • Name:

    Coversyl Arginine 10mg orodispersible tablets

  • Company:
    info
  • Active Ingredients:

    Perindopril arginine

  • Legal Category:

    Product subject to medical prescription which may be renewed (B)

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 20/03/19

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 20/3/2019

Click on this link to Download PDF directly

Servier Laboratories Ireland Ltd

Servier Laboratories Ireland Ltd

Company Products

Medicine NameActive Ingredients
Medicine Name ACERYCAL Active Ingredients Amlodipine besilate, Perindopril arginine
Medicine Name Coverdine Active Ingredients Amlodipine, Indapamide, Perindopril
Medicine Name Coversyl Arginine 10mg Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine 10mg orodispersible tablets Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine 5mg Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine 5mg orodispersible tablets Active Ingredients Perindopril arginine
Medicine Name Coversyl Arginine Plus 10mg/2.5mg film-coated tablets Active Ingredients Indapamide, Perindopril arginine
Medicine Name Coversyl Arginine Plus 2.5mg/0.625mg film-coated tablets Active Ingredients Indapamide, Perindopril arginine
Medicine Name Coversyl Arginine Plus 5 mg/1.25 mg film-coated tablets Active Ingredients Indapamide, Perindopril arginine
Medicine Name Diamicron MR 30 mg Active Ingredients Gliclazide
Medicine Name Diamicron MR 60mg Active Ingredients Gliclazide
Medicine Name LIPERCOSYL Active Ingredients Atorvastatin calcium trihydrate, Perindopril arginine
Medicine Name LIPOCOMB Active Ingredients ezetimibe, Rosuvastatin Calcium
Medicine Name LONSURF Active Ingredients Tipiracil hydrochloride, Trifluridine
Medicine Name Natrilix SR Active Ingredients Indapamide
Medicine Name Oncaspar 750 U/ml powder for solution for injection/infusion Active Ingredients pegaspargase
Medicine Name ONIVYDE Active Ingredients Irinotecan hydrochloride trihydrate
Medicine Name Pixuvri 29 mg Active Ingredients Pixantrone dimaleate
Medicine Name Procoralan film-coated tablets Active Ingredients Ivabradine hydrochloride
Medicine Name Valdoxan 25mg Film-coated Tablets Active Ingredients Agomelatine
Medicine Name Vastarel 20mg Active Ingredients Trimetazidine dihydrochloride
1 - 0 of 21 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 20 March 2019 PIL

Reasons for updating

  • Change to section 4 - possible side effects

Updated on 20 March 2019

Reasons for updating

  • Change to section 4.8 - Undesirable effects

Updated on 20 March 2019

Reasons for updating

  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Updated on 29 May 2018

Reasons for updating

  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 29 May 2018 PIL

Reasons for updating

  • Change to section 2 - what you need to know - contraindications
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 4 - possible side effects

Updated on 30 May 2017 SPC

Reasons for updating

  • Change to section 6.3 - Shelf life

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

section 6.3 Shelf-life

Updated on 30 May 2017

Reasons for updating

  • New SmPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Updated on 8 November 2016 SPC

Reasons for updating

  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
  • Change to section 4.8 - Undesirable effects

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

-          4.4          Special warnings and precautions for use

Hypersensitivity/Angioedema: Addition of concomitant use of mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)

 

-          4.5          Interaction with other medicinal products and other forms of interaction

                                                Concomitant use not recommended (see section 4.4):Addition of: Racecadotril and mTOR inhibitors (e.g. sirolimus, everolimus, temsirolimus)

 

-          4.8          Undesirable effects

Tabulated list of adverse reactions

Skin and Subcutaneous Tissue Disorders: Addition of: Psoriasis aggravation

 

Updated on 3 November 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 3 November 2016 PIL

Reasons for updating

  • Change to section 4 - possible side effects
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 2 - interactions with other medicines, food or drink

Updated on 18 August 2016 SPC

Reasons for updating

  • New SPC for new product

Legal category: Product subject to medical prescription which may be renewed (B)

Free text change information supplied by the pharmaceutical company

None provided

Updated on 17 August 2016 PIL

Reasons for updating

  • New PIL for new product